There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics (VBLT) and Spectrum Pharmaceuticals (SPPI) with bullish sentiments.
Vascular Biogenics (VBLT)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vascular Biogenics, with a price target of $3. The company’s shares closed yesterday at $1.26.
Ramakanth observed:
“We maintain our Buy rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying a 6x multiple to our 2026 sales estimate discounted at 18%; and 2) price-earnings multiple analysis applying a 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.”
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.7% and a 29.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vascular Biogenics with a $3.25 average price target.
See today’s analyst top recommended stocks >>
Spectrum Pharmaceuticals (SPPI)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Spectrum Pharmaceuticals, with a price target of $41. The company’s shares closed yesterday at $7.83, close to its 52-week low of $6.22.
According to TipRanks.com, White is a 5-star analyst with an average return of 15.0% and a 48.2% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Aileron Therapeutics Inc.
Currently, the analyst consensus on Spectrum Pharmaceuticals is a Strong Buy with an average price target of $24.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.